Robinson MK - Search Results

1

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK. D'Souza JW, et al. Among authors: robinson mk. PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014. PLoS One. 2014. PMID: 25386657 Free PMC article.

2

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Reddy S, et al. Among authors: robinson mk. Clin Cancer Res. 2011 Mar 15;17(6):1509-20. doi: 10.1158/1078-0432.CCR-10-1654. Epub 2010 Dec 21. Clin Cancer Res. 2011. PMID: 21177408 Free PMC article.

3

Oligoclonal antibodies to target the ErbB family.

D'Souza JW, Robinson MK. D'Souza JW, et al. Among authors: robinson mk. Expert Opin Biol Ther. 2015 Jul;15(7):1015-21. doi: 10.1517/14712598.2015.1042362. Epub 2015 May 2. Expert Opin Biol Ther. 2015. PMID: 25936923 Free PMC article. Review.

4

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Robinson MK, et al. Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7. Br J Cancer. 2008. PMID: 18841159 Free PMC article.

5

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Tang Y, et al. Among authors: robinson mk. J Immunol. 2007 Sep 1;179(5):2815-23. doi: 10.4049/jimmunol.179.5.2815. J Immunol. 2007. PMID: 17709495

6

Immuno-positron emission tomography in cancer models.

Reddy S, Robinson MK. Reddy S, et al. Among authors: robinson mk. Semin Nucl Med. 2010 May;40(3):182-9. doi: 10.1053/j.semnuclmed.2009.12.004. Semin Nucl Med. 2010. PMID: 20350627 Free PMC article. Review.

7

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

D'Souza JW, Hensley H, Doss M, Beigarten C, Torgov M, Olafsen T, Yu JQ, Robinson MK. D'Souza JW, et al. Among authors: robinson mk. J Nucl Med. 2017 Jan;58(1):175-180. doi: 10.2967/jnumed.116.178780. Epub 2016 Aug 18. J Nucl Med. 2017. PMID: 27539844 Free PMC article.

8

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Robinson MK, et al. Cancer Res. 2005 Feb 15;65(4):1471-8. doi: 10.1158/0008-5472.CAN-04-2008. Cancer Res. 2005. PMID: 15735035

9

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.

Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Horak E, et al. Among authors: robinson mk. Cancer Biother Radiopharm. 2005 Dec;20(6):603-13. doi: 10.1089/cbr.2005.20.603. Cancer Biother Radiopharm. 2005. PMID: 16398612

10

Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Robinson MK, et al. Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250. Clin Cancer Res. 2008. PMID: 18245551 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page